Question to the Department of Health and Social Care:

To ask His Majesty's Government what proportion of the Innovative Medicines Fund budget was spent in each of past two financial years as (1) total spend, and (2) a percentage of the overall budget.

The Innovative Medicines Fund (IMF), established in June 2022, provides time‑limited access to innovative non‑cancer medicines while further evidence is generated to address uncertainties identified by the NICE appraisal committee. Following a managed access period of up to five years, NICE reviews the updated evidence to determine whether the medicine should be routinely commissioned by the NHS.

NHS England spent £2 million on drugs funded through the IMF in both 2023/24 and 2024/25. This is 0.6% of the £340 million allocated to the IMF.

In the 2025/26 financial year to date, IMF expenditure has been £18 million, 5.3% of allocated funds. Any underspend on medicines funded through the IMF is diverted to other specialised services.